Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
- 1 July 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (7) , 763-770
- https://doi.org/10.1124/dmd.30.7.763
Abstract
Irinotecan (CPT-11) is a water-soluble camptothecin (CPT) derivative that has been recently approved in the United States for patients as a first-line therapy in advanced colorectal cancer. Phase I clinical trials using oral CPT-11 have shown poor and variable oral bioavailability. The present study was designed to investigate the intestinal absorption and efflux mechanisms of CPT-11 using in vitro cell culture models, Caco-2 cells, and engineered Madine-Darby canine kidney (MDCK) II cells overexpressing P-glycoprotein (Pgp), canalicular multispecific organic anion transporter (cMOAT), and multidrug resistance-associated protein (MRP1). The intestinal absorptive and secretory transport of CPT-11 was investigated using Caco-2 cell monolayers. Secretory transport was concentration-dependent and saturable. The secretory efflux permeability (Peff) of CPT-11 decreased with decreasing temperature, with an estimated activation energy of 19.6 ± 2.9 kcal/mol suggesting the involvement of active transporters. The involvement of potential secretory transporters was further characterized in MDCK II cells. The secretory efflux carrier permeability (Pc) was ∼4- and ∼2-fold greater in MDCK II/Pgp and MDCK II/cMOAT cells than that in MDCK II/wild-type cells. Furthermore, the secretory effluxPeff of CPT-11 was significantly decreased by Pgp inhibitors, elacridar (GF120918) (IC50 = 0.38 ± 0.06 μM) and verapamil (IC50 = 234 ± 48 μM) in MDCK II/Pgp cells and by cMOAT inhibitor 3-([{3-(2-[7-chloro-2-quinolinyl]ethyl)phenyl}-{(3-dimethylamino-3-oxoprphyl)-thio}-methyl]-thio) propanoic acid (MK571) (IC50 = 469 ± 60 μM) in MDCK II/cMOAT cells. Overall, the current study suggests that Pgp and cMOAT are capable of mediating the efflux of CPT-11 in vitro. Since both Pgp and cMOAT are expressed in the intestine, liver, and kidney, it is likely that these efflux transporters play a significant role limiting the oral absorption and disposition of this important anticancer drug.This publication has 28 references indexed in Scilit:
- Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1Advanced Drug Delivery Reviews, 2001
- Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics†Journal of Pharmaceutical Sciences, 1998
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1997
- Genetic dissection of the function of mammalian P-glycoproteinsTrends in Genetics, 1997
- Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestineProceedings of the National Academy of Sciences, 1997
- P-glycoprotein and multidrug resistanceCurrent Opinion in Genetics & Development, 1996
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicityInternational Journal of Cancer, 1992
- The S-phase cytotoxicity of camptothecinExperimental Cell Research, 1991
- Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityJournal of Medicinal Chemistry, 1989